- Home
- OXM vs KNSA Comparison
OXM vs KNSA Comparison
Compare OXM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- KNSA
- Stock Information
- Founded
- OXM 1942
- KNSA 2015
- Country
- OXM United States
- KNSA United Kingdom
- Employees
- OXM N/A
- KNSA N/A
- Industry
- OXM Apparel
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- KNSA Health Care
- Exchange
- OXM Nasdaq
- KNSA Nasdaq
- Market Cap
- OXM 1.3B
- KNSA 1.3B
- IPO Year
- OXM N/A
- KNSA 2018
- Fundamental
- Price
- OXM $84.84
- KNSA $18.73
- Analyst Decision
- OXM Sell
- KNSA Strong Buy
- Analyst Count
- OXM 3
- KNSA 5
- Target Price
- OXM $77.00
- KNSA $36.60
- AVG Volume (30 Days)
- OXM 324.2K
- KNSA 469.7K
- Earning Date
- OXM 12-11-2024
- KNSA 02-26-2025
- Dividend Yield
- OXM 3.16%
- KNSA N/A
- EPS Growth
- OXM N/A
- KNSA N/A
- EPS
- OXM 0.95
- KNSA N/A
- Revenue
- OXM $1,530,524,000.00
- KNSA $384,098,000.00
- Revenue This Year
- OXM N/A
- KNSA $60.05
- Revenue Next Year
- OXM $3.08
- KNSA $36.74
- P/E Ratio
- OXM $89.60
- KNSA N/A
- Revenue Growth
- OXM N/A
- KNSA 54.41
- 52 Week Low
- OXM $72.24
- KNSA $16.56
- 52 Week High
- OXM $113.88
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- OXM 55.00
- KNSA 38.56
- Support Level
- OXM $84.88
- KNSA $18.27
- Resistance Level
- OXM $89.86
- KNSA $19.05
- Average True Range (ATR)
- OXM 2.99
- KNSA 0.61
- MACD
- OXM 0.31
- KNSA -0.05
- Stochastic Oscillator
- OXM 67.61
- KNSA 34.42
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates a majority of its revenue from the Tommy Bahama division.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.